Prelude Therapeutics logo

Prelude Therapeutics share price today

(PRLD)

Prelude Therapeutics share price is $1.3 & ₹110.47 as on 21 Dec 2024, 2.30 'hrs' IST

$1.3

0.41

(46.4%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Prelude Therapeutics share price in Dollar and Rupees. Guide to invest in Prelude Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Prelude Therapeutics. Get details on the Indian mutual funds that are investing in Prelude Therapeutics. Get Analyst recommendations and forecasts along with all the Prelude Therapeutics's financials.

Prelude Therapeutics share price movements

  • Today's Low: $0.94
    Today's High: $1.43

    Day's Volatility :34.23%

  • 52 Weeks Low: $0.80
    52 Weeks High: $6.80

    52 Weeks Volatility :88.29%

Prelude Therapeutics Returns

PeriodPrelude Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-45.15%
-11.1%
0.0%
6 Months
-66.92%
-6.0%
0.0%
1 Year
-69.12%
2.7%
0.0%
3 Years
-90.2%
0.6%
-19.7%

Prelude Therapeutics Key Statistics

in dollars & INR

Previous Close
$0.888
Open
$0.9374
Today's High
$1.4292
Today's Low
$0.94
Market Capitalization
$48.9M
Today's Volume
$4.2M
52 Week High
$6.8
52 Week Low
$0.7966
Revenue TTM
$3.0M
EBITDA
$-141.6M
Earnings Per Share (EPS)
$-1.77
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-66.64%

How to invest in Prelude Therapeutics from India?

It is very easy for Indian residents to invest directly in Prelude Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Prelude Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Prelude Therapeutics or PRLD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Prelude Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Prelude Therapeutics shares which would translate to 0.654 fractional shares of Prelude Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Prelude Therapeutics, in just a few clicks!

Returns in Prelude Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Prelude Therapeutics investment value today

Current value as on today

₹1,71,317

Returns

₹71,317

(+71.32%)

Returns from Prelude Therapeutics Stock

₹69,121 (false-69.12%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Prelude Therapeutics

0%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Prelude Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 21, 2024. 0% more investors are searching Prelude Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Prelude Therapeutics

  • Orbimed Advisors, LLC

    19.82%

  • Baker Bros Advisors LP

    18.40%

  • Deerfield Management Co

    6.84%

  • Boxer Capital LLC

    3.10%

  • T. Rowe Price Associates, Inc.

    1.99%

  • BlackRock Inc

    1.94%

Analyst Recommendation on Prelude Therapeutics

Sell

    11%Buy

    44%Hold

    44%Sell

Based on 9 Wall street analysts offering stock ratings for Prelude Therapeutics(by analysts ranked 0 to 5 stars)

Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
4
4
3
Sell
4
4
4

Analyst Forecast on Prelude Therapeutics

What analysts predicted

Upside of 284.62%

Current:

$1.30

Target:

$5.00

Insights on Prelude Therapeutics

  • Price Movement

    In the last 7 days, PRLD stock has moved up by 62.5%
  • PRLD vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 103.5%
  • PRLD vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 113.5%
  • Price to Sales

    ForPRLD every $1 of sales, investors are willing to pay $32.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Prelude Therapeutics Technicals Summary

Sell

Neutral

Buy

Prelude Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Prelude Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prelude Therapeutics Inc
34.41%
-66.92%
-69.12%
-90.2%
-95.04%
Regeneron Pharmaceuticals, Inc.
-4.87%
-34.03%
-17.11%
13.66%
87.56%
Biontech Se
2.87%
30.56%
7.36%
-56.46%
225.6%
Alnylam Pharmaceuticals, Inc.
-3.21%
10.11%
28.49%
30.99%
109.19%
Vertex Pharmaceuticals Incorporated
-11.93%
-16.36%
-1.97%
78.33%
80.59%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prelude Therapeutics Inc
NA
NA
NA
-1.77
-0.67
-0.39
NA
2.84
Regeneron Pharmaceuticals, Inc.
17.51
17.51
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.17
0.55
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prelude Therapeutics Inc
Sell
$48.9M
-95.04%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$77.8B
87.56%
17.51
33.61%
Biontech Se
Buy
$26.7B
225.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.8B
109.19%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$102.1B
80.59%
32.84
-4.51%

About Prelude Therapeutics

prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.
Organization
Prelude Therapeutics
Employees
128
CEO
Dr. Krishna Vaddi D.V.M., Ph.D.
Industry
Health Technology

Management People of Prelude Therapeutics

NameTitle
Dr. Krishna Vaddi D.V.M., Ph.D.
Founder, CEO & Director
Dr. Edna Huang M.D.
President & Chief Medical Officer
Mr. Bryant David Lim J.D.
Interim CFO, Chief Legal Officer & Corporate Secretary
Ms. Aimee Crombie Ph.D.
Senior VP and Head of Strategic Planning & Operations
Dr. Madhu Pudipeddi Ph.D.
Senior Vice President of Technical Operations
Dr. Peggy A. Scherle Ph.D.
Chief Scientific Officer
Ms. Lindsey Trickett
Vice President of Investor Relations
Ms. Michele Porreca M.B.A.
Chief People Officer
Dr. Andrew P. Combs Ph.D.
Executive VP & Chief Chemistry Officer
Mr. Naveen Babbar Ph.D.
Senior Vice President of Translation Medicine

Important FAQs about investing in Prelude Therapeutics from India :

What is Prelude Therapeutics share price today?

Prelude Therapeutics share price today stands at $1.30, Open: $0.94 ; Previous Close: $0.89 ; High: $1.43 ; Low: $0.94 ; 52 Week High: $6.80 ; 52 Week Low: $0.80. The stock opens at $0.94, after a previous close of $0.89. The stock reached a daily high of $1.43 and a low of $0.94, with a 52-week high of $6.80 and a 52-week low of $0.80.

Can Indians buy Prelude Therapeutics shares?

Yes, Indians can invest in the Prelude Therapeutics (PRLD) from India.

With INDmoney, you can buy Prelude Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Prelude Therapeutics at zero transaction cost.

How can I buy Prelude Therapeutics shares from India?

It is very easy to buy Prelude Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Prelude Therapeutics be purchased?

Yes, you can buy fractional shares of Prelude Therapeutics with INDmoney app.

What are the documents required to start investing in Prelude Therapeutics stocks?

To start investing in Prelude Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Prelude Therapeutics

Today’s highest price of Prelude Therapeutics (PRLD) is $1.43.

Today’s lowest price of Prelude Therapeutics (PRLD) is $0.94.

What is today's market capitalisation of Prelude Therapeutics

Today's market capitalisation of Prelude Therapeutics PRLD is 48.9M

What is the 52 Week High and Low Range of Prelude Therapeutics

  • 52 Week High

    $6.80

  • 52 Week Low

    $0.80

What are the historical returns of Prelude Therapeutics?

  • 1 Month Returns

    34.41%

  • 3 Months Returns

    -66.92%

  • 1 Year Returns

    -69.12%

  • 5 Years Returns

    -95.04%

Who is the Chief Executive Officer (CEO) of Prelude Therapeutics

Dr. Krishna Vaddi D.V.M., Ph.D. is the current Chief Executive Officer (CEO) of Prelude Therapeutics.